<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38695461</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1678-4464</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Cadernos de saude publica</Title><ISOAbbreviation>Cad Saude Publica</ISOAbbreviation></Journal><ArticleTitle>[Overview of long COVID in Brazil: a preliminary analysis of a survey to think about health policies].</ArticleTitle><Pagination><StartPage>e00094623</StartPage><MedlinePgn>e00094623</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00094623</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/0102-311XPT094623</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0102-311X2024000401500</ELocationID><Abstract><AbstractText>Characterized by symptoms that remain or appear for the first time within three months of SARS-CoV-2 infection, long COVID can manifest itself in different ways, including in non-hospitalized or asymptomatic cases. Thus, this study offers an overview of long COVID in Brazil, especially of its diagnosis, symptoms, and challenges for new health management. Data from a study that investigated long COVID in people affected by COVID-19 were used. These original data stem from a survey with adult Brazilians (aged 18 years or older) who had COVID-19 that collected information from March 14 to April 14, 2022, by a questionnaire on social media. The questionnaire addressed sociodemographic characteristics, history of COVID-19 infections, vaccination against the disease, investigation of health status and quality of life before and after COVID-19, and search and access to treatment. Of the 1,728 respondents, 720 were considered eligible for analysis, of which 496 (69%) had long COVID. Individuals with long COVID reported clinical manifestations such as anxiety (80%), memory loss (78%), generalized pain (77%), lack of attention (75%), fatigue (73%), hair loss (71%), sleep changes (70%), mood swings (62%), malaise (60%), and joint pain (59%). Most sought health services during and after the acute phase of COVID-19 (94 and 80%, respectively), representing the need to structure the healthcare system for these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batista</LastName><ForeName>Karina Barros Calife</ForeName><Initials>KBC</Initials><Identifier Source="ORCID">0000-0002-7038-8069</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Ci&#xea;ncias M&#xe9;dicas da Santa Casa de S&#xe3;o Paulo, S&#xe3;o Paulo, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Michelle Vieira</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0003-0224-0991</Identifier><AffiliationInfo><Affiliation>Universidade de Bras&#xed;lia, Bras&#xed;lia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Aggeu Magalh&#xe3;es, Funda&#xe7;&#xe3;o Oswaldo Cruz, Recife, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barberia</LastName><ForeName>Lorena Guadalupe</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0001-6319-543X</Identifier><AffiliationInfo><Affiliation>Faculdade de Filosofia, Letras e Ci&#xea;ncias Humanas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Erica Tatiane da</ForeName><Initials>ETD</Initials><Identifier Source="ORCID">0000-0001-6478-3532</Identifier><AffiliationInfo><Affiliation>Fiocruz Bras&#xed;lia, Funda&#xe7;&#xe3;o Oswaldo Cruz, Bras&#xed;lia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedi</LastName><ForeName>Vaneide Daciane</ForeName><Initials>VD</Initials><Identifier Source="ORCID">0000-0003-4294-7238</Identifier><AffiliationInfo><Affiliation>Fiocruz Bras&#xed;lia, Funda&#xe7;&#xe3;o Oswaldo Cruz, Bras&#xed;lia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Minist&#xe9;rio da Sa&#xfa;de, Bras&#xed;lia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontes</LastName><ForeName>B&#xe1;rbara Maia Lima Madeira</ForeName><Initials>BMLM</Initials><Identifier Source="ORCID">0000-0002-7127-2498</Identifier><AffiliationInfo><Affiliation>Universidade de Bras&#xed;lia, Bras&#xed;lia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araujo</LastName><ForeName>Gui</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8131-1553</Identifier><AffiliationInfo><Affiliation>Swansea University, Swansea, U. K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreira</LastName><ForeName>Rafael da Silveira</ForeName><Initials>RDS</Initials><Identifier Source="ORCID">0000-0003-0079-2901</Identifier><AffiliationInfo><Affiliation>Instituto Aggeu Magalh&#xe3;es, Funda&#xe7;&#xe3;o Oswaldo Cruz, Recife, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade Federal de Pernambuco, Recife, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrosa</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4633-2567</Identifier><AffiliationInfo><Affiliation>Instituto Aggeu Magalh&#xe3;es, Funda&#xe7;&#xe3;o Oswaldo Cruz, Recife, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verotti</LastName><ForeName>Mariana Pastorello</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0003-3732-372X</Identifier><AffiliationInfo><Affiliation>Fiocruz Bras&#xed;lia, Funda&#xe7;&#xe3;o Oswaldo Cruz, Bras&#xed;lia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Claudio Maierovitch Pessanha</ForeName><Initials>CMP</Initials><Identifier Source="ORCID">0000-0002-1461-7082</Identifier><AffiliationInfo><Affiliation>Fiocruz Bras&#xed;lia, Funda&#xe7;&#xe3;o Oswaldo Cruz, Bras&#xed;lia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flor&#xea;ncio</LastName><ForeName>Anna Catharina</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-1281-192X</Identifier><AffiliationInfo><Affiliation>Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amorim</LastName><ForeName>Melania Maria Ramos de</ForeName><Initials>MMR</Initials><Identifier Source="ORCID">0000-0003-1047-2514</Identifier><AffiliationInfo><Affiliation>Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Panorama da COVID longa no Brasil: an&#xe1;lise preliminar de um inqu&#xe9;rito para pensar pol&#xed;ticas de sa&#xfa;de.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Cad Saude Publica</MedlineTA><NlmUniqueID>8901573</NlmUniqueID><ISSNLinking>0102-311X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="Y">Health Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText>Caracterizada por sintomas que permanecem ou aparecem pela primeira vez em at&#xe9; tr&#xea;s meses ap&#xf3;s a infec&#xe7;&#xe3;o pelo SARS-CoV-2, a COVID longa pode se manifestar de diferentes formas, inclusive entre casos n&#xe3;o hospitalizados ou assintom&#xe1;ticos. Nesse sentido, este artigo apresenta um panorama da COVID longa no Brasil, com &#xea;nfase no diagn&#xf3;stico, nos sintomas e nos desafios para a nova gest&#xe3;o da sa&#xfa;de. Foram utilizados dados de um estudo realizado com objetivo de investigar a COVID longa em pessoas acometidas pela COVID-19, com dados originais de um inqu&#xe9;rito com indiv&#xed;duos brasileiros adultos (18 anos ou mais) que tiveram COVID-19, coletados entre 14 de mar&#xe7;o e 14 de abril de 2022, por meio de question&#xe1;rio divulgado em redes sociais. O question&#xe1;rio abordou caracter&#xed;sticas sociodemogr&#xe1;ficas, hist&#xf3;rico de infec&#xe7;&#xf5;es por COVID-19, vacina&#xe7;&#xe3;o contra a doen&#xe7;a, investiga&#xe7;&#xe3;o da situa&#xe7;&#xe3;o de sa&#xfa;de e da qualidade de vida antes e ap&#xf3;s a COVID-19, al&#xe9;m da busca e acesso a tratamento. Dos 1.728 respondentes, 720 foram considerados eleg&#xed;veis para a an&#xe1;lise. Desses, 496 (69%) tiveram COVID longa. Os indiv&#xed;duos com COVID longa reportaram manifesta&#xe7;&#xf5;es cl&#xed;nicas como ansiedade (80%), perda de mem&#xf3;ria (78%), dor generalizada (77%), falta de aten&#xe7;&#xe3;o (75%), fadiga (73%), queda de cabelo (71%), altera&#xe7;&#xf5;es de sono (70%), altera&#xe7;&#xf5;es de humor (62%), indisposi&#xe7;&#xe3;o (60%) e dor nas articula&#xe7;&#xf5;es (59%). A maioria procurou os servi&#xe7;os de sa&#xfa;de durante e ap&#xf3;s a fase aguda de COVID-19 (94% e 80%, respectivamente), o que representa a necessidade de estruturar o sistema de sa&#xfa;de para atender esses pacientes.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Caracterizado por s&#xed;ntomas que permanecen o aparecen por primera vez dentro de los tres meses posteriores a la infecci&#xf3;n por SARS-CoV-2, la COVID larga puede manifestarse de diferentes formas, incluso entre casos no hospitalizados o asintom&#xe1;ticos. En este sentido, este art&#xed;culo presenta un panorama la COVID larga en Brasil, con &#xe9;nfasis en el diagn&#xf3;stico, los s&#xed;ntomas y los desaf&#xed;os para la nueva gesti&#xf3;n de la salud. Se utilizaron datos de una encuesta realizada para investigar la COVID larga en personas afectadas por COVID-19. Se trata de datos originales de una encuesta con individuos brasile&#xf1;os adultos (18 a&#xf1;os o m&#xe1;s), que tuvieron COVID-19, con datos recolectados entre el 14 de marzo y el 14 de abril de 2022, por medio de un cuestionario divulgado en las redes sociales. El cuestionario abord&#xf3; caracter&#xed;sticas sociodemogr&#xe1;ficas, historial de infecciones por COVID-19, vacunaci&#xf3;n contra la enfermedad, investigaci&#xf3;n de la situaci&#xf3;n de salud y de la calidad de vida antes y despu&#xe9;s de COVID-19, adem&#xe1;s de la b&#xfa;squeda y acceso a tratamiento. De los 1.728 encuestados, 720 fueron considerados elegibles para el an&#xe1;lisis. De ellos, 496 (69%) ten&#xed;an COVID larga. Las personas con COVID larga informaron manifestaciones cl&#xed;nicas como ansiedad (80%), p&#xe9;rdida de memoria (78%), dolor generalizado (77%), falta de atenci&#xf3;n (75%), fatiga (73%), p&#xe9;rdida de cabello (71%), cambios en el sue&#xf1;o (70%), cambios de humor (62%), malestar (60%) y dolor en las articulaciones (59%). La mayor&#xed;a recurri&#xf3; a los servicios de salud durante y despu&#xe9;s de la fase aguda de COVID-19 (94% y 80%, respectivamente), lo que representa la necesidad de estructurar el sistema de salud para atender a estos pacientes.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>13</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>13</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>7</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38695461</ArticleId><ArticleId IdType="pmc">PMC11057476</ArticleId><ArticleId IdType="doi">10.1590/0102-311XPT094623</ArticleId><ArticleId IdType="pii">S0102-311X2024000401500</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Europe  At least 17 million people in the WHO European Region experienced long
COVID in the first two years of the pandemic; millions may have to live with
it for years to come.  [20/Dez/2023].  
 https://www.who.int/europe/news/item/13-09-2022-at-least-17-million-people-in-the-who-european-region-experienced-long-covid-in-the-first-two-years-of-the-pandemic--millions-may-have-to-live-with-it-for-years-to-come
.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns Hopkins Medicine  Long Covid: long-term effects of COVID-19.  [16/Nov/2022].  
 https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-long-haulers-long-term-effects-of-covid19
.</Citation></Reference><Reference><Citation>Uddin T, Rahim HR, Khandaker MN. The impact of COVID-19 and the challenges of post-COVID rehabilitation in a developing country. Front Rehabil Sci. 2022;2:746061&#x2013;746061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9397726</ArticleId><ArticleId IdType="pubmed">36188760</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Agarwal A, Alwan N, Luyckx VA. Long COVID long-term health outcomes and implications for policy and research. Nat Rev Nephrol. 2023;19:1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9628426</ArticleId><ArticleId IdType="pubmed">36319780</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Understanding long COVID: a modern medical challenge. Lancet. 2021;398:725&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389978</ArticleId><ArticleId IdType="pubmed">34454656</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns Hopkins University  Coronavirus Resource Center.  [17/Nov/2022].  
 https://coronavirus.jhu.edu/map.html
.</Citation></Reference><Reference><Citation>Minist&#xe9;rio da Sa&#xfa;de Portaria n&#xba; 377, de 22 de fevereiro de 2022. Institui incentivo financeiro federal de custeio destinado aos munic&#xed;pios e ao Distrito Federal, em car&#xe1;ter excepcional e tempor&#xe1;rio, para apoiar as a&#xe7;&#xf5;es das equipes e os servi&#xe7;os de Aten&#xe7;&#xe3;o Prim&#xe1;ria &#xe0; Sa&#xfa;de voltados ao cuidado &#xe0;s pessoas com condi&#xe7;&#xf5;es p&#xf3;s-covid, no contexto da Emerg&#xea;ncia em Sa&#xfa;de P&#xfa;blica de Import&#xe2;ncia Nacional decorrente do SARS-CoV-2. Di&#xe1;rio Oficial da Uni&#xe3;o. 2022 Feb 23;</Citation></Reference><Reference><Citation>Oliveira J. Primeiro na Regi&#xe3;o Norte, Centro Especializado de Reabilita&#xe7;&#xe3;o p&#xf3;s-Covid
&#xe9; inaugurado em Manaus.  [Nov/2022].  
 https://www.manaus.am.gov.br/noticia/primeiro-na-regiaonorte-centro-especializado-de-reabilitacao-pos-covid-e-inaugurado-em-manaus/
</Citation></Reference><Reference><Citation>Comit&#xea; T&#xe9;cnico Assistencial para Enfrentamento &#xe0; Pandemia de
Covid-19, Secretaria de Estado da Sa&#xfa;de P&#xfa;blica do Rio Grande do
Norte  Protocolo de tratamento do novo coronav&#xed;rus (casos
suspeitos/confirmados).  [Nov/2022].  
 http://www.adcon.rn.gov.br/ACERVO/sesap/DOC/DOC000000000252277.PDF
.</Citation></Reference><Reference><Citation>Secretaria de Estado da Sa&#xfa;de  Cartilha do Programa Reabilita Goi&#xe1;s.  [Nov/2022].  
 https://www.saude.go.gov.br/files/escola-saude/cartilhas/Cartilha-do-Programa-Reabilita-Goias.pdf
.</Citation></Reference><Reference><Citation>Comiss&#xe3;o de Transi&#xe7;&#xe3;o Governamental  Relat&#xf3;rio do Grupo T&#xe9;cnico de Sa&#xfa;de.  [Jun/2023].  
 https://conselho.saude.gov.br/images/noticias/2023/GT-Saude_Relatario_Final_1.pdf
.</Citation></Reference><Reference><Citation>Marques RM, Piola SF, Ock&#xe9;-Reis CO. Marques RM, Piola SF, Roa AC, compilers. In: Sistema de sa&#xfa;de no Brasil: organiza&#xe7;&#xe3;o e financiamento. Rio de Janeiro: Associa&#xe7;&#xe3;o Brasileira de Economia da Sa&#xfa;de; Bras&#xed;lia: Minist&#xe9;rio da Sa&#xfa;de/Organiza&#xe7;&#xe3;o Pan-Americana da Sa&#xfa;de; 2016. O financiamento do SUS numa perspectiva futura. pp. 247&#x2013;258.</Citation></Reference><Reference><Citation>Servo LMS, Santos MAB, Vieira FS, S&#xe1; e Benevides RP, compilers. Financiamento do SUS e Covid-19: hist&#xf3;rico, participa&#xe7;&#xf5;es federativas e respostas &#xe0; pandemia. Sa&#xfa;de Debate. 2021;44(spe. 4):e407</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>